戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ost patients have impaired function of these small fibers.
2 brane of the soma, axon initial segment, and small fibers.
3 mprises over 20 large muscle fibers and four small fibers.
4 s between large/small fibers and sympathetic/small fibers.
5 tients had functional abnormalities of these small fibers; 29 patients (60%) had abnormal sweat test
6 t permitted rapid, noninvasive evaluation of small-fiber alterations in patients and could be used to
7 hat premium products release more amounts of small fibers and disintegrate more slowly than average o
8 s; and abnormal communications between large/small fibers and sympathetic/small fibers.
9       This loss was accompanied with loss of small fiber axon counts and declining metabolic reserve
10 (+) and anti-HMGCR(+) Abs, a large number of small fibers corresponding to both atrophic and regenera
11                      However, CCM quantifies small fiber damage rapidly and noninvasively and detects
12 eal confocal microscopy (IVCCM) can quantify small fiber damage.
13 s (n = 46, 54.8%), patients with significant small fiber deficits (n = 38, 45.2%) reported higher ave
14 on, compared to patients without significant small fiber deficits (n = 46, 54.8%), patients with sign
15 rtion of former critically ill patients show small fiber deficits which seem to be associated with in
16 s, we aimed to identify associations between small fiber deficits, pain, health-related quality of li
17 nstrate the potential for selective block of small fiber diameters.
18 ng, and numbness are generally attributed to small fiber dysfunction.
19 ema, and abnormal sweating-are explicable by small-fiber dysfunction.
20 against pre-equilibrium SPME (using multiple small fibers), equilibrium SPME, and liquid extraction m
21       Secondary measures included functional small fiber evaluation, such as autonomic (heart rate, b
22 of Cardiovascular Autonomic Reflex Tests and Small Fibers from Skin Biopsies (QASAT) was used to grad
23 mportant clinical implications for assessing small-fiber function in neuropathies and neuropathic pai
24 alues in thermal testing, indicating reduced small fiber functioning.
25 ve patient care and broaden our knowledge of small-fiber functions.
26                                   Similar to small fibers, Ia axons are vulnerable to diabetes, and t
27 pler be used to directly collect and analyze small fibers in addition to the widely accepted sampling
28 ) with obesity, diabetes, and aging (reduced small-fiber innervation and nerve/synaptic/growth-cone/v
29 ullary cores that have a structure and dense small-fiber innervation resembling that of tooth pulp.
30 in amyloidosis often present with large- and small-fiber involvement.
31  fibers is reduced by 50%, and the number of small fibers is also occasionally reduced.
32                                              Small-fiber lesions are easily missed on examination and
33 howed length-dependent somatic and autonomic small fiber loss, more severely expressed in patients wi
34 ed to treat autoimmune autonomic and sensory small fiber neuropathy (ASFN).
35       We established a novel mouse model for small fiber neuropathy (SFN) in which grin1, the gene th
36                                              Small fiber neuropathy (SFN) is an important feature of
37                                              Small fiber neuropathy (SFN) is clinically and etiologic
38                                      Painful small fiber neuropathy (SFN) may be caused by gain-of-fu
39 cerns regarding a potential association with small fiber neuropathy (SFN).
40 data are available on the natural history of small fiber neuropathy (SNF).
41 n, topical application of capsaicin causes a small fiber neuropathy and is associated with a delay in
42 hese mice develop sensory loss with a distal small fiber neuropathy and peripheral myelinopathy.
43                                Patients with small fiber neuropathy for which no other cause has been
44                  Objective quantification of small fiber neuropathy in patients with human immunodefi
45        This report describes 2 patients with small fiber neuropathy in whom vasculitis was found to b
46 e wound healing that isolated the effects of small fiber neuropathy on the healing process.
47 of diabetes is an acute and severely painful small fiber neuropathy that occurs in association with a
48 suggesting a patchy manifestation pattern of small fiber neuropathy.
49  studies were consistent with a dysautonomic small fiber neuropathy.
50 of healthy participants versus patients with small fiber neuropathy.
51 ion disturbance requiring pacemaker, 1.0% in small-fiber neuropathy (3 studies; 904 patients screened
52                                   Idiopathic small-fiber neuropathy (I-SFN), clinically characterized
53                                              Small-fiber neuropathy (SFN) is a disorder of peripheral
54                                              Small-fiber neuropathy (SFN) is characterized by injury
55 nful disorders inherited erythromelalgia and small-fiber neuropathy (SFN).
56 with recordings from 17 female patients with small-fiber neuropathy and 9 female controls.
57 iceptors in the fibromyalgia group, 114 from small-fiber neuropathy patients, and 66 from controls.
58 f silent nociceptors in fibromyalgia, 34% in small-fiber neuropathy, and 2.2% in controls.
59 silent nociceptors in fibromyalgia, 22.7% in small-fiber neuropathy, and 3.7% in controls.
60 exhibit hyperexcitability resembling that in small-fiber neuropathy, but high activity-dependent slow
61 oximately 30% of cases of idiopathic painful small-fiber neuropathy.
62 s of 104 patients with painful predominantly small-fiber neuropathy.
63 a, they did not show any protection from the small-fiber neuropathy.
64 w (Bcl-2l2) is required for the viability of small fiber nociceptive sensory neurons.
65                                      Using a small fiber-optic camera (endoscope), 46 patients were e
66 hile oxidative stress has been implicated in small-fiber painful peripheral neuropathies, antioxidant
67 tolerated is limited by the development of a small-fiber painful peripheral neuropathy.
68 ibromyalgia population demonstrates signs of small fiber pathology as measured by CCM.
69                                The extent of small fiber pathology is related to symptom severity in
70 Spinal inhibitory dysfunction and peripheral small fiber pathology may contribute to the clinical phe
71                                              Small fiber pathology was detected in the cornea of 51%
72 h outcomes of skin biopsies in patients with small fiber pathology.
73 for 12/15-lipoxygenase in diabetic large and small fiber peripheral and autonomic neuropathies.
74 al changes characteristic for both large and small fiber peripheral diabetic neuropathies and axonal
75 nsgenes resulted in restoration of large and small fiber peripheral nerve function.
76  nerves from chronic CRPS-I patients confirm small-fiber-predominant pathology.
77                                      Indeed, small-fiber-predominant polyneuropathies cause CRPS-like
78                                              Small fibers sense pain and temperature but also regulat
79 hat the animals had some normally conducting small fiber sensory nerves.
80 trophic factor that promotes the survival of small fiber sensory neurons and sympathetic neurons in t
81 ablish bcl-w(-/-) mice as an animal model of small fiber sensory neuropathy and provide new insight r
82 hies that affect large nerve fibers; painful small fiber sensory neuropathy has not previously been d
83                                              Small fiber sensory neuropathy is a common disorder in w
84    In the majority of patients, the cause of small fiber sensory neuropathy is unknown, and treatment
85 nation, pressure threshold, and quantitative small fiber sensory testing.
86                                              Small-fiber sensory and autonomic symptoms are early pre
87 everity, and distribution of both large- and small-fiber sensory loss and which approaches and techni
88 s/1 mm may be used as a surrogate measure of small-fiber sensory loss but appear not to correlate clo
89       In contrast, P2X3 mRNA is localized to small-fiber sensory neurons and produces less mechanosen
90  mSCs and both large-fiber nerve bundles and small-fiber sensory neurons; report that muscle mSCs tra
91                Microfibers, characterized as small fibers shed from textiles that are less than 5 mm
92 performing functional rather than structural small fiber studies when evaluating erythromelalgia.
93  assessment, neurophysiology assessment, and small fiber tests: skin punch biopsy, corneal confocal m
94     Changes in the density of intraepidermal small fibers, the ultrastructure of Remak bundles, and t
95 ecialized technique is needed for collecting small fibers to provide a more representative estimate o
96 rge-fiber topography, but was not changed in small-fiber topography with these inhibitors.
97 lgia is associated with a structural loss of small fibers using the ENFD technique and to compare thi
98 lgia is associated with a structural loss of small fibers using the ENFD technique and to compare thi
99                                 In addition, small fibers were initially detected in most of the samp